Introduction of new alternative pipeline using multiplexed fast COLD‑PCR together with sequencing approach highlighting pharmacoeconomics by detection of CYP variants

In precision medicine, multiple factors are involved in clinical decision-making because of ethnic and racial genetic diversity, family history and other health factors. Although advanced techniques have evolved, there is still an economic obstacle to pharmacogenetic (PGx) implementation in developing countries. The aim of the present study was to provide an alternative pipeline that roughly estimate patient carrier type and prescreen out wild-type samples before sequencing or genotyping to determine genetic status. Fast co-amplification at lower denaturation temperature (COLD)-PCR was used to differentiate genetic variant non-carriers from carriers. The majority of drugs are hepatically cleared by cytochrome P450 (CYP) enzymes and genes encoding CYP enzymes are highly variable. Of all the CYPs, CYP2 family of CYP2C9, CYP2C19, and CYP2D6 isoforms have clinically significant impact on drugs of PGx testing. Therefore, five variants associated with these CYPs were selected for preliminary testing with this novel pipeline. For fast COLD-PCR, the optimal annealing temperature and critical denaturation temperature were determined and evaluated via Sanger sequencing of 27 randomly collected samples. According to precise Tc, to perform in a single-reaction is difficult. However, in this study, this issue was resolved by combination of precise Tc using 10+10+20 cycles. The results showed 100% sensitivity and specificity, with perfect agreement (κ=1.0) compared with Sanger sequencing. The present study provides a prescreening platform by introducing multiplex fast COLD-PCR as a pharmacoeconomic implementation. Our study just present in five variants which are not enough to describe patient metabolic status. Therefore, other actional genetic variants are still needed to cover the actual patient's genotypes. Nevertheless, the proposed method can well-present its efficiency and reliability for serving as a PGx budget platform in the future.

[1]  L. Teh,et al.  A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges , 2022, The Pharmacogenomics Journal.

[2]  M. Rietschel,et al.  Methodology for clinical genotyping of CYP2D6 and CYP2C19 , 2021, Translational Psychiatry.

[3]  C. Sukasem,et al.  Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population , 2021, Scientific Reports.

[4]  B. Wilffert,et al.  Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone , 2021, Scientific Reports.

[5]  M. Nijenhuis,et al.  Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines , 2021, Frontiers in Pharmacology.

[6]  R. Altman,et al.  Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications , 2020, Clinical and translational science.

[7]  T. Clement,et al.  Guidelines for Sanger sequencing and molecular assay monitoring , 2020, Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc.

[8]  Niels Westergaard,et al.  Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug–Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients , 2020, Journal of personalized medicine.

[9]  E. Pearson,et al.  Drug–drug–gene interactions and adverse drug reactions , 2019, The Pharmacogenomics Journal.

[10]  Harris H Wang,et al.  Synthetic sequence entanglement augments stability and containment of genetic information in cells , 2019, Science.

[11]  K. Na-Bangchang,et al.  CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in South‐East and East Asian populations: A systematic review , 2019, Journal of clinical pharmacy and therapeutics.

[12]  F. Nosten,et al.  Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study , 2018, Malaria Journal.

[13]  I. Kallikas,et al.  Fast Temperature-Gradient COLD PCR for the enrichment of the paternally inherited SNPs in cell free fetal DNA; an application to non-invasive prenatal diagnosis of β-thalassaemia , 2018, PloS one.

[14]  G. Özhan,et al.  CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population , 2016, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[15]  M. Luzum,et al.  Physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education. , 2016, Personalized medicine.

[16]  C. Castellani,et al.  COLD-PCR and microarray: two independent highly sensitive approaches allowing the identification of fetal paternally inherited mutations in maternal plasma , 2016, Journal of Medical Genetics.

[17]  Hua-sheng Xiao,et al.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray. , 2015, International journal of clinical and experimental medicine.

[18]  T. Mamiya,et al.  How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. , 2014, Pharmacogenomics.

[19]  A. Gaedigk.  Complexities of CYP2D6 gene analysis and interpretation , 2013, International review of psychiatry.

[20]  Y. Daali,et al.  Applications of CYP450 Testing in the Clinical Setting , 2013, Molecular Diagnosis & Therapy.

[21]  G. Makrigiorgos,et al.  Enrichment of Mutations in Multiple DNA Sequences Using COLD-PCR in Emulsion , 2012, PloS one.

[22]  M. Ferrari,et al.  Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment. , 2012, Clinical chemistry.

[23]  G. Botti,et al.  Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. , 2011, International journal of oncology.

[24]  M. Rossbach,et al.  Translational genomics in personalized medicine – scientific challenges en route to clinical practice , 2012, The HUGO Journal.

[25]  S. Preskorn,et al.  Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant? , 2011, Journal of psychiatric practice.

[26]  Eun-Young Kim,et al.  Cytochrome P450 CYP2 genes in the common cormorant: Evolutionary relationships with 130 diapsid CYP2 clan sequences and chemical effects on their expression. , 2011, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[27]  S. Santagata,et al.  Multiplex amplification coupled with COLD-PCR and high resolution melting enables identification of low-abundance mutations in cancer samples with low DNA content. , 2011, The Journal of molecular diagnostics : JMD.

[28]  L. Capelle,et al.  COLD PCR HRM: a highly sensitive detection method for IDH1 mutations , 2010, Human mutation.

[29]  S. Hamilton-Dutoit,et al.  Increased sensitivity of KRAS mutation detection by high‐resolution melting analysis of COLD‐PCR products , 2010, Human mutation.

[30]  Tsuyoshi Fukuda,et al.  Simple and accurate determination of CYP2D6 gene copy number by a loop-mediated isothermal amplification method and an electrochemical DNA chip. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[31]  Magnus Ingelman-Sundberg,et al.  The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects , 2010, Human Genomics.

[32]  Cheng Li,et al.  Two‐round coamplification at lower denaturation temperature–PCR (COLD‐PCR)‐based sanger sequencing identifies a novel spectrum of low‐level mutations in lung adenocarcinoma , 2009, Human mutation.

[33]  H. Koeppen,et al.  Application of COLD-PCR for improved detection of KRAS mutations in clinical samples , 2009, Modern Pathology.

[34]  A. Sajantila,et al.  Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales , 2009, Pharmacogenetics and genomics.

[35]  F. Monzon.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing , 2009 .

[36]  Leif Bertilsson,et al.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants , 2006, Clinical pharmacology and therapeutics.

[37]  W. Tassaneeyakul,et al.  CYP2C19 genetic polymorphism in Thai, Burmese and Karen populations. , 2006, Drug metabolism and pharmacokinetics.

[38]  A. Alderborn,et al.  Determination of CYP2D6 gene copy number by pyrosequencing. , 2005, Clinical chemistry.

[39]  L. D. Bradford,et al.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. , 2002, Pharmacogenomics.

[40]  C. Meisel,et al.  Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. , 2000, Pharmacogenomics.

[41]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.